Swiss Life Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $956K | Buy |
16,713
+1,038
| +7% | +$56.9K | ﹤0.01% | 715 |
|
|
2026
Q1 | $885K | Buy |
15,675
+2,837
| +22% | +$165K | ﹤0.01% | 679 |
|
|
2025
Q4 | $763K | Sell |
12,838
-7,447
| -37% | -$405K | ﹤0.01% | 689 |
|
|
2025
Q3 | $1.1M | Sell |
20,285
-54,282
| -73% | -$3.1M | 0.01% | 621 |
|
|
2025
Q2 | $4.1M | Buy |
74,567
+58,073
| +352% | +$3.42M | 0.02% | 419 |
|
|
2025
Q1 | $1.17M | Buy |
16,494
+4,818
| +41% | +$324K | 0.01% | 595 |
|
|
2024
Q4 | $766K | Buy |
+11,676
| New | +$782K | 0.01% | 623 |
|
|
2024
Q3 | – | Sell |
-2,698
| Closed | -$222K | – | 632 |
|
|
2024
Q2 | $222K | Sell |
2,698
-900
| -25% | -$74.9K | ﹤0.01% | 572 |
|
|
2024
Q1 | $314K | Sell |
3,598
-1,145
| -24% | -$103K | ﹤0.01% | 514 |
|
|
2023
Q4 | $459K | Sell |
4,743
-199
| -4% | -$17.6K | 0.01% | 581 |
|
|
2023
Q3 | $437K | Sell |
4,942
-34,856
| -88% | -$3.1M | 0.01% | 583 |
|
|
2023
Q2 | $3.45M | Buy |
39,798
+1,063
| +3% | +$100K | 0.05% | 392 |
|
|
2023
Q1 | $3.77M | Buy |
38,735
+2,649
| +7% | +$275K | 0.06% | 375 |
|
|
2022
Q4 | $3.75M | Sell |
36,086
-1,376
| -4% | -$129K | 0.06% | 321 |
|
|
2022
Q3 | $3.18M | Buy |
37,462
+1,740
| +5% | +$155K | 0.05% | 358 |
|
|
2022
Q2 | $2.97M | Buy |
35,722
+6,263
| +21% | +$499K | 0.05% | 382 |
|
|
2022
Q1 | $2.27M | Sell |
29,459
-180
| -0.6% | -$15.1K | 0.03% | 406 |
|
|
2021
Q4 | $2.62M | Hold |
29,639
| – | – | 0.03% | 406 |
|
|
2021
Q3 | $2.29M | Hold |
29,639
| – | – | 0.03% | 409 |
|
|
2021
Q2 | $2.47M | Sell |
29,639
-2,163
| -7% | -$171K | 0.03% | 420 |
|
|
2021
Q1 | $2.4M | Sell |
31,802
-614
| -2% | -$50.2K | 0.03% | 404 |
|
|
2020
Q4 | $2.84M | Hold |
32,416
| – | – | 0.04% | 389 |
|
|
2020
Q3 | $2.46M | Buy |
32,416
+2,570
| +9% | +$260K | 0.04% | 307 |
|
|
2020
Q2 | $3.68M | Hold |
29,846
| – | – | 0.06% | 219 |
|
|
2020
Q1 | $2.53M | Buy |
29,846
+1,749
| +6% | +$151K | 0.05% | 249 |
|
|
2019
Q4 | $2.38M | Hold |
28,097
| – | – | 0.05% | 320 |
|
|
2019
Q3 | $1.89M | Buy |
28,097
+2,584
| +10% | +$199K | 0.02% | 358 |
|
|
2019
Q2 | $2.18M | Buy |
25,513
+7,179
| +39% | +$614K | 0.03% | 309 |
|
|
2019
Q1 | $1.63M | Buy |
+18,334
| New | +$1.7M | 0.02% | 332 |
|
|
2018
Q3 | – | Sell |
-21,041
| Closed | -$1.98M | – | 538 |
|
|
2018
Q2 | $1.98M | Buy |
+21,041
| New | +$1.84M | 0.03% | 305 |
|
Other funds holding BMRN
VPC
Swiss Life Asset Management's BMRN Position: Q2 2026 in Review
Swiss Life Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 6.6% in Q2 2026, buying an estimated $56.9K and bringing the position to 16,713 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #715.
Swiss Life Asset Management first reported a position in BMRN in Q2 2018 and has held it in 30 quarters since. The position peaked at $4.1M in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Swiss Life Asset Management held 16,713 shares of BioMarin Pharmaceuticals worth $956K as of Q2 2026.
- Swiss Life Asset Management bought 1,038 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $56.9K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #715 holding.
- Swiss Life Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- Swiss Life Asset Management's BioMarin Pharmaceuticals position peaked at $4.1M in Q2 2025.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.